KYTX · Kyverna Therapeutics, Inc.
$8.61
-0.23 (-2.60%)
At close · Aug 26
Market Cap
$544.22M
Shares
61.84M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$161.31M
-26.5%
FY2025
Diluted EPS
-$3.64
-9.3%
FY2025
Operating Cash Flow
-$153.71M
-34.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $115.33M | $133.72M | $112.47M | $49.92M | |
| $43.6M | $36.11M | $30.13M | $12.48M | |
| $1.65M | $1.8M | $2.13M | $1.71M | |
| $158.93M | $169.83M | $142.6M | $62.41M | |
| -$158.93M | -$169.83M | -$142.6M | -$62.41M | |
| $1.79M | $489K | $142K | $187K | |
| $8.16M | $9.09M | $15.36M | $2.28M | |
| $6.29M | $8.52M | $15.13M | $2.04M | |
| — | $0 | $0 | $0 | |
| -$152.64M | -$161.31M | -$127.48M | -$60.37M | |
| -$152.76M | -$161.32M | -$127.38M | -$60.34M | |
| USD/shares | — | -$3.64 | -$3.33 | -$89.61 |
| USD/shares | — | -$3.64 | -$3.33 | -$89.61 |
| shares | — | 44.26M | 38.33M | 673.62K |
| shares | — | 44.26M | 38.33M | 673.62K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.82×
EV/EBIT
—
Peer median 9.64×
P/E (TTM)
—
Peer median 12.65×
Peer medians compare against the 310 similar-size Biotechnology companies (of 534 listed).
Key facts
CIK
1994702
CUSIP
501976104
13F (30d)
108 filings
107 filers
Visit website
Investor relations